A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
Brett King, Emma Guttman-Yassky, Elena Peeva, Anindita Banerjee, Rodney Sinclair, Ana B Pavel, Linda Zhu, Lori Ann Cox, Brittany Craiglow, Linda Chen, Christopher Banfield, Karen Page, Weidong Zhang, Michael S Vincent
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | MOSBY-ELSEVIER | Published : 2021
BACKGROUND: Alopecia areata (AA) is an autoimmune form of hair loss with limited treatments. OBJECTIVE: To evaluate the efficacy and safety of the Janus kinase inhibitors ritlecitinib and brepocitinib in patients who have AA with ≥ 50% scalp hair loss. METHODS: Patients were randomized to once-daily ritlecitinib, brepocitinib, or placebo. The primary efficacy endpoint was a 24-week change from baseline in the Severity of Alopecia Tool (SALT) score. The key secondary efficacy endpoint was the proportion of patients achieving 30% improvement in SALT score (SALT30). RESULTS: The ritlecitinib, brepocitinib, and placebo groups included 48, 47, and 47 patients, respectively. At week 24, least-squa..View full abstract
The authors thank the patients involved in this study. Editorial and medical writing support was provided by Jennica Lewis, PharmD, of Engage Scientific Solutions and was funded by Pfizer.